CN105683162A - N-(4-氯-2-羟基-3((3s)-3-哌啶基磺酰基)苯基)-n’-(3-氟-2-甲基苯基)脲的氢溴酸盐 - Google Patents
N-(4-氯-2-羟基-3((3s)-3-哌啶基磺酰基)苯基)-n’-(3-氟-2-甲基苯基)脲的氢溴酸盐 Download PDFInfo
- Publication number
- CN105683162A CN105683162A CN201480061455.2A CN201480061455A CN105683162A CN 105683162 A CN105683162 A CN 105683162A CN 201480061455 A CN201480061455 A CN 201480061455A CN 105683162 A CN105683162 A CN 105683162A
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- situation
- combination product
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 78
- 239000003814 drug Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000013066 combination product Substances 0.000 claims description 25
- 229940127555 combination product Drugs 0.000 claims description 25
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 19
- 229940124803 CXCR2 antagonist Drugs 0.000 claims description 17
- 239000002573 chemokine receptor CXCR2 antagonist Substances 0.000 claims description 17
- -1 (3S)-3-piperidinylsulfonyl Chemical group 0.000 claims description 11
- 239000004202 carbamide Substances 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 abstract description 29
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 3
- NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 abstract 1
- 239000002585 base Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 10
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 10
- 239000005482 chemotactic factor Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000004890 Interleukin-8 Human genes 0.000 description 9
- 108090001007 Interleukin-8 Proteins 0.000 description 9
- 239000003513 alkali Substances 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 7
- 102100026236 Interleukin-8 Human genes 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000003448 neutrophilic effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 5
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 5
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000003399 chemotactic effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 4
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 3
- 101150093802 CXCL1 gene Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 3
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 3
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102100036154 Platelet basic protein Human genes 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RGHNJXZEOKUKBD-NRXMZTRTSA-N (2r,3r,4r,5s)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-NRXMZTRTSA-N 0.000 description 1
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 description 1
- MMZYCBHLNZVROM-UHFFFAOYSA-N 1-fluoro-2-methylbenzene Chemical compound CC1=CC=CC=C1F MMZYCBHLNZVROM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- AFTCWZSEWTXWTL-BTQNPOSSSA-N 2-hydroxy-n,n-dimethyl-3-[[2-[[(1r)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide;hydrate Chemical compound O.N([C@H](CC)C=1OC(C)=CC=1)C(C(C1=O)=O)=C1NC1=CC=CC(C(=O)N(C)C)=C1O AFTCWZSEWTXWTL-BTQNPOSSSA-N 0.000 description 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229940123025 Beta2 integrin antagonist Drugs 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 229940126669 CCR4 antagonist Drugs 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 229940122296 IKK2 inhibitor Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical group [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 1
- 229960001469 fluticasone furoate Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- WYVBISCFCHREDA-UHFFFAOYSA-N n-cycloheptyl-6,7-dimethoxy-2-(4-piperidin-1-ylpiperidin-1-yl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N2CCC(CC2)N2CCCCC2)=NC=1NC1CCCCCC1 WYVBISCFCHREDA-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 239000002750 tryptase inhibitor Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- MWLSOWXNZPKENC-UHFFFAOYSA-N zileuton Chemical compound C1=CC=C2SC(C(N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-UHFFFAOYSA-N 0.000 description 1
- 229940052267 zyflo Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种化合物,其为N-(4-氯-2-羟基-3((3S)-3-哌啶基磺酰基)苯基)-N’-(3-氟-2-甲基苯基)脲的氢溴酸盐,含有所述化合物的组合物、组合和药物及其制备方法。本发明还涉及所述化合物、组合产品、组合物和药物的用途。
Description
发明领域
本发明涉及N-(4-氯-2-羟基-3((3S)-3-哌啶基磺酰基)苯基)-N’-(3-氟-2-甲基苯基)脲的新型氢溴酸盐,含有所述化合物的组合物、组合产品和药物,以及所述化合物的制备方法。本发明还涉及所述化合物、组合产品、组合物和药物在治疗CXCR2拮抗剂所指示的疾病或状况上的用途。
发明背景
CXCR2是经充分表征的、针对多个趋化因子的G蛋白偶联受体,所述多个趋化因子共享Glu-Leu-Arg(ELR)基序,其包括白细胞介素8(IL-8,CXCL8)以及受生长调节的致癌基因α、β和γ(GROα、β、γ或CXCL1、2、3),所述受生长调节的致癌基因涉及将中性粒细胞聚集到损伤部位[Reutershan,J.(2006)DrugNewsPerspect19:615-623]。CXCR2主要在中性粒细胞(PMN)上表达,但也可在其它白细胞(如单核细胞)上表达。在人类临床前(研究)中已表明,CXCR2的拮抗作用能有效阻断PMN响应于刺激(如LPS、香烟烟雾或暴露于臭氧)而聚集到肺部[ThatcherTH(2005)AmJourPhysLungCellMolPhys289:L322-L328;ReutershanJ(2006)JClinInvest116:695-702;HolzO,KhaliliehS,Ludwig-SengpielA,WatzH,StryszakP,SoniP,TsaiM,SadehJ,MagnussenH.SCH527123,anovelCXCR2antagonist,inhibitsozone-inducedneutrophiliainhealthysubjects.EurRespirJ2010;35:564-570;LazaarAL,SweeneyLE,MacDonaldAJ,AlexisNE,ChenC,Tal-SingerR.SB-656933,anovelCXCR2selectiveantagonist,inhibitsexvivoneutrophilactivationandozone-inducedairwayinflammationinhumans.Br.J.Clin.Pharmacol.72:282-293(2011)]。CXCR2与其各种趋化因子配体间的相互作用的选择性拮抗作用为减少导致多种疾病进展的潜在炎症提供了可能的策略[ChapmanRW,PhillipsaJE,HipkinaRW,CurranaAK,LundellaD和FineJS.CXCR2antagonistsforthetreatmentofpulmonarydisease。
Pharmacol.Ther.2009;121(1):55-68],正如在对呼吸道疾病患者的初步研究中所证实的(NairP,GagaM,ZervasE,AlaghaK,HargreaveFE,O'ByrnePM,StryszakP,GannL,SadehJ,ChanezP;StudyInvestigators.SafetyandefficacyofaCXCR2antagonistinpatientswithsevereasthmaandsputumneutrophils:arandomized,placebo-controlledclinicaltrial.ClinExpAllergy2012;42:1097-2103;RennardSI,DaleDC,DonohureJF,KanniessF,MagnussenH,SutherlandER,WatzH,LuS,StryszakP,RosenbergE,StaudingerH.CXCR2antagonistMK-7123–aphase2proof-of-concepttrialforchronicobstructivepulmonarydisease.AmJRespirCritCareMed2013;187:A6071)。
具有ELR基序(例如,CXCL1/GROα、CXCL8/IL-8)的CXC趋化因子对于聚集在多种器官环境中介导病理的炎症细胞很重要。病理与例如,从活化的中性粒细胞中不恰当地释放的水解酶和反应性氧物质有关。另一方面,在大多数细菌感染期间,此趋化因子应答代表了关键的第一道防线,但即使这样,ELR+CXC趋化因子应答也可以通过其活化(具有CXCR1和CXCR2受体的)炎症细胞的能力而加剧病理。尽管这些趋化因子应答在许多环境中至关重要,但炎症细胞应答足以破坏治疗工具的识别而阻断ELR+趋化因子才是我们所关注的。
ELR趋化因子通过炎症细胞的CXCR1和CXCR2受体而趋化并活化炎症细胞。CXCR1对CXCL8和CXCL6具有特异性,而CXCR2以高亲和力结合CXCL8,但也以稍低一点的亲和力结合CXCL1、CXCL5和CXCL6。经人类CXCR1或CXCR2转染的细胞系中的CXCL8信号传递诱导等效的趋化应答。响应于CXCL8的中性粒细胞胞浆游离Ca++变化以及细胞脱颗粒也是通过两种受体介导的,但据报道,呼吸爆发和磷脂酶D的活化则完全依赖于CXCR1。另一方面,已报道了CXCR2,而非CXCR1,的非肽拮抗剂会拮抗CXCL8介导的中性粒细胞趋化,但不会拮抗细胞活化。最后,有充分证据表明,趋化因子在炎症应答期间常常过度表达。
WO2007/124424公开了可用于治疗由IL-8介导的疾病状态的化合物,包括化合物N-{4-氯-2-羟基-3-[-3-哌啶基磺酰基]苯基}-N’-(3-氟-2-甲基苯基)脲及其对映异构体N-{4-氯-2-羟基-3-[(3S)-3-哌啶基磺酰基]苯基}-N’-(3-氟-2-甲基苯基)脲。
在本领域,仍然需要能够拮抗CXCR2的化合物以用于治疗。
发明概述
在一个方面,提供了N-{4-氯-2-羟基-3-[-3-哌啶基磺酰基]苯基}-N’-(3-氟-2-甲基苯基)脲的新型氢溴酸盐,特别是对映异构体N-{4-氯-2-羟基-3-[(3S)-3-哌啶基磺酰基]苯基}-N’-(3-氟-2-甲基苯基)脲的氢溴酸盐(本发明的化合物)。
在本发明的另外的方面,提供了本发明的化合物以用于治疗,特别是治疗CXCR2拮抗剂所指示的疾病或状况。
在本发明的另外的方面,提供了药物组合物,其包含本发明的化合物以及一种或多种药学上可接受的载体、稀释剂和赋形剂。
在本发明的另外的方面,提供了治疗CXCR2拮抗剂所指示的疾病或状况的方法,其包括施用治疗有效量的本发明的化合物。
在本发明的另外的方面,提供了本发明的化合物在制备药物上的用途,所述药物用于治疗CXCR2拮抗剂所指示的疾病或状况。
在另外的方面,提供了组合产品,其包含本发明的化合物和至少一种另外的治疗剂。
在另外的方面,提供了药物组合物,其包含本发明的化合物和至少一种另外的治疗剂以及一种或多种药学上可接受的载体、稀释剂和赋形剂。
在另外的方面,提供了组合产品以用于治疗,特别是治疗CXCR2拮抗剂所指示的疾病或状况,所述组合产品包含本发明的化合物和至少一种另外的治疗剂。
在另外的方面,提供了治疗CXCR2拮抗剂所指示的疾病或状况的方法,其包括向有此需要的人施用治疗有效量的组合产品,所述组合产品包含本发明的化合物和至少一种另外的治疗剂。
在另外的方面,提供了组合产品在制备药物上的用途,所述药物用于治疗CXCR2拮抗剂所指示的疾病或状况,所述组合产品包含本发明的化合物和至少一种另外的治疗剂。
在另外的方面,提供了在哺乳动物(特别是人类)中抑制IL8与其受体结合的方法,其包括施用治疗有效量的本发明的化合物。
附图列表
图1:HBr盐提供了增强的溶出度而不会在低胃部pH下发生胶凝作用
图2:HBr盐于升高的胃部pH下提供了最大的溶出度
发明详述
据发现,氢溴酸盐相对于游离碱显示出了多项优势,使其特别适用于治疗CXCR2拮抗剂所指示的疾病或状况,例如,慢性阻塞性肺病(COPD)。
具体地讲,相比游离碱,氢溴酸盐在更高的pH下显示出改善的溶解度和溶出概况。许多COPD患者也服用质子泵抑制剂并因而可具有高于平均的胃部pH。此类患者将不会得到与健康患者相同的游离碱暴露量,并因此氢溴酸盐的增大的溶解度和溶出度使其在此类患者体内的暴露量增加。
如本文中所用,术语“有效量”意指(例如研究人员或临床医生)所追寻的将会引起组织、系统、动物或人的生物或医疗应答的药品或药剂的量。此外,术语“治疗有效量”意指,相比尚未接收到此量的对应个体,对于疾病、病症或副作用的治疗、痊愈、预防或改善带来了改进的,或降低了疾病或病症的进展速率的任何量。能有效增强正常生理功能的量也包括在该术语的范围内。
如本文中所用,术语“药学上可接受的”指代这样的化合物、材料、组合物和剂型:其在合理的医学判断范围内,适用于与人体和动物组织接触而无过量的毒性、刺激或其它问题或并发症,并与合理的效/险比相称。
本发明的化合物可以溶剂化和非溶剂化的形式存在。如本文中所用,术语“溶剂化物”指代由溶质(在本发明中,具有式(I)的化合物或盐)和溶剂形成的具有可变化学计量的配合物。用于本发明的目的的此类溶剂不会干扰溶质的生物活性。技术人员将认识到,药学上可接受的溶剂化物可以是为晶体化合物而形成的,其中在结晶过程中将溶剂分子掺入到晶格中。掺入的溶剂分子可以是水分子或非水性分子,如乙醇、异丙醇、DMSO、乙酸、乙醇胺和乙酸乙酯分子。掺入水分子的晶格通常被称为“水合物”。水合物包括化学计量的水合物以及含有可变水量的组合物。在一个实施方案中,本发明的化合物为半水合物。
本发明的化合物可具有以不止一种形式结晶的能力,这一特性被称为多晶型现象,并且应当理解,此类多晶型形式(“多晶型物”)在本发明的范围之内。多晶型现象通常可作为对温度或压力或二者的变化的响应而发生,并且还可以由结晶过程中的变化引起。可以通过本领域已知的各种物理特性(如X射线衍射图、溶解度和熔点)来辨别多晶型物。
虽然本发明的化合物可作为未加工的化学品施用以用于治疗,但是也可能作为药物组合物而提供活性成分。因此,本发明还提供了药物组合物,其包含本发明的化合物以及一种或多种药学上可接受的载体、稀释剂或赋形剂。所述一种或多种载体、稀释剂或赋形剂必须从与组合物的其它成分相容并且不会危害到其接受者的意义上而言是可接受的。根据本发明的另一个方面,还提供了制备药物组合物的方法,所述药物组合物包含药剂或其药学上可接受的盐以及一种或多种药学上可接受的载体、稀释剂或赋形剂。药物组合物可用于治疗和/或预防本文所述的任何状况。
药物组合物可以单位剂量的形式提供,每个单位剂量含有预定量的活性成分。优选的单位剂量组合物含有日剂量或分剂量或其适当级分的活性成分。因此,此类单位剂量可每天施用一次或不止一次。此类药物组合物可通过药学领域熟知的任何方法制备。
药物组合物可适于通过任何适当途径施用,例如通过口服(包括经颊或舌下)、直肠、吸入、鼻内、局部(包括经颊、舌下或透皮)、阴道或肠道外(包括皮下、肌内、静脉内或皮内)途径。此类组合物可通过药学领域已知的任何方法制备,例如通过将活性成分与一种或多种载体或赋形剂结合起来。
适于口服的药物组合物可作为分立单位提供,如胶囊或片剂、粉剂或颗粒剂、在水性或非水性液体中的溶液剂或悬浮剂、可食用泡沫(foam或whip)或水包油液态乳剂或油包水液态乳剂。
例如,为了以片剂或胶囊的形式口服,可将活性药物组分与口服的无毒药学上可接受的惰性载体(如乙醇、甘油、水等)结合。通过将化合物减小到合适的细小粒度并与经过类似制备的药物载体如可食用的碳水化合物(例如,淀粉或甘露糖醇)混合来制备粉剂。还可提供调味剂、防腐剂、分散剂和染色剂。
通过如上所述制备粉末混合物并填充入成形的明胶外壳中而制得胶囊。可在填充操作前,向粉末混合物中加入助流剂和润滑剂如硅溶胶、滑石、硬脂酸镁、硬脂酸钙或固态聚乙二醇。还可加入崩解剂或增溶剂(如琼脂-琼脂、碳酸钙或碳酸钠)以在摄入胶囊时改善药物的可用性。
此外,当需要或必要时,还可在混合物中掺入合适的粘结剂、助流剂、润滑剂、甜味剂、调味剂、崩解剂和染色剂。合适的粘结剂包括淀粉、明胶、天然糖类(如葡萄糖或β-乳糖)、玉米甜味剂、天然及合成的树胶(如阿拉伯树胶、黄蓍胶或藻酸钠)、羧甲基纤维素、聚乙二醇、蜡等。用于这些剂型中的润滑剂包括油酸钠、硬脂酸钠、硬脂酸镁、苯甲酸钠、醋酸钠、氯化钠等。崩解剂包括但不限于淀粉、甲基纤维素、琼脂、膨润土、黄原胶等。片剂的配制是例如通过制备粉末混合物、成粒或成条、加入润滑剂和崩解剂并压制成片剂。粉末混合物可通过如下制备:将经过适当粉碎的化合物与如上所述的稀释剂或基料混合,并任选地与粘结剂(如羧甲基纤维素、藻胶、明胶或聚乙烯吡咯烷酮)、溶液阻滞剂(如石蜡)、吸收促进剂(如季盐)和/或吸附剂(如膨润土、高岭土或磷酸二钙)混合。可通过用粘结剂(如糖浆、淀粉糊、阿拉伯胶浆或纤维素溶液或聚合物材料溶液)润湿粉末混合物并迫使其穿过筛网而使粉末混合物成粒。作为备选的成粒方案,可使粉末混合物通过压片机,而其结果是:没有完全成形的条会破碎成颗粒。可通过加入硬脂酸、硬脂酸盐、滑石或矿物油来润滑颗粒以防止其粘在片剂成型模具上。然后将经润滑的混合物压制成片剂。本发明的化合物还可以与自由流动的惰性载体结合并且不经过成粒或成条的步骤而直接压制成片剂。可提供由紫胶封闭涂层组成的透明或不透明的保护涂层、糖衣或聚合物材料涂层以及蜡抛光涂层。可在这些涂层中加入染料以区分不同的单位剂量。
如本文中所用,本发明的化合物包括N-(4-氯-2-羟基-3((3S)-3-哌啶基磺酰基)苯基)-N’-(3-氟-2-甲基苯基)脲的氢溴酸盐的所有溶剂化物、配合物、多晶型物、经放射标记的衍生物。
可以将口服液(如溶液剂、糖浆和酏剂)制备成剂量单位形式以使得给定数量含有预定量的化合物。可以通过将化合物溶于经适当调味的水溶液中来制备糖浆,而酏剂则是通过使用无毒的酒精媒介物而制备的。可以通过将化合物分散到无毒的媒介物中来配制悬浮剂。还可以加入增溶剂和乳化剂(如乙氧基化的异硬脂醇和聚氧乙烯山梨醇醚)、防腐剂、风味添加剂(如薄荷油或天然甜味剂或糖精或其它人造甜味剂)等。
在适当情况下,可以将用于口服的剂量单位组合物微胶囊化。还可以例如通过将颗粒材料包覆或嵌入聚合物、蜡等来制备组合物以延长或维持释放。
本发明的化合物也可以脂质体递送系统的形式(如小单室脂质体、大单室脂质体以及多室脂质体)施用。脂质体可由多种磷脂(如胆固醇、硬脂胺或磷脂酰胆碱)形成。
适于透皮施用的药物组合物可以独立贴剂的形式提供,旨在与接受者的表皮长时间保持紧密接触。
适于局部施用的药物组合物可以被配制成软膏、霜剂、悬浮剂、洗剂、粉剂、溶液剂、糊剂、凝胶、喷雾剂、气雾剂或油。
为了治疗眼部或其它外部组织(例如口和皮肤),优选地将组合物作为局部软膏或霜剂施用。当被配制成软膏时,活性成分可与石蜡基的或可与水混溶的软膏基料一起采用。可选地,活性成分可与水包油的霜剂基料或油包水的基料一起被配制成霜剂。
适于在眼部局部施用的药物组合物包括滴眼剂,其中活性成分被溶于或悬浮于合适的载体(特别是水性溶剂)中。
适于在口中局部施用的药物组合物包括锭剂、含片和漱口剂。
适于直肠施用的药物组合物可以栓剂或灌肠剂的形式提供。
用于鼻腔或吸入施用的剂型可以被方便地配制成气雾剂、溶液剂、悬浮滴剂、凝胶或干粉剂。
适于阴道施用的药物组合物可以阴道栓剂、棉条、霜剂、凝胶、糊剂、泡沫或喷雾制剂的形式提供。
适于肠道外施用的药物组合物包括:水性和非水性的无菌注射溶液,所述注射溶液可含有抗氧化剂、缓冲液、抑菌剂和溶质,其使得组合物与预期接受者的血液等渗;以及水性和非水性的无菌悬浮液,其可包含悬浮剂和增稠剂。组合物可以单位剂量或多剂量容器的形式(例如密闭的安瓿和小瓶)提供,并且可保存在冷冻干燥的(冻干的)条件下,仅需在即将使用前加入无菌液体载体(例如水)用于注射即可。即兴注射溶液和悬浮液可由无菌粉剂、颗粒剂和片剂制备。
应当理解,除了以上特别提到的成分外,组合物还可根据所考虑的制剂类型而包含本领域中的其它常规药剂,例如那些适于口服的可包含调味剂。
本发明的化合物的治疗有效量将取决于多个因素,包括,例如,个体的年龄和体重、需要治疗的精确状况及其严重程度、制剂的性质以及施用途径,并且将最终由主治医师或兽医判断。具体地讲,待治疗的个体是哺乳动物,特别是人。
可以日剂量施用药剂。该量可以每日单剂量或每日多个(如两个、三个、四个、五个或六个)分剂量(使总的日剂量相同)的方式施用。
对于本文公开的本发明的化合物的所有使用方法而言,日口服剂量方案将优选约0.01至约80mg/kg总体重。日肠道外剂量方案为约0.001至约80mg/kg总体重。日局部剂量方案将优选0.1mg至150mg,每日施用一至四次、优选二或三次。日吸入剂量方案将优选每日约0.01mg/kg至约1mg/kg。本领域技术人员还应当认识到,本发明的化合物的各个剂量的最佳数量和时间间隔将由所治疗的状况的性质和程度,施用形式、途径和部位,以及接受治疗的具体患者所决定,并且此类最佳条件可以通过常规技术确定。本领域技术人员还将认识到,最佳疗程,即,在限定的天数内每天施用本发明的化合物的剂量数,可以由本领域技术人员使用常规的疗程确定测试而确定。上述全部均涉及游离碱的量。
本发明的化合物可用于制造药物以在人类或其它哺乳动物中预防或治疗CXCR2拮抗剂所指示的任何疾病状态。
因此,本发明提供了治疗CXCR2拮抗剂所指示的疾病或状况的方法,而该方法包括施用有效量的本发明的化合物。
CXCR2拮抗剂指示了许多疾病状态。趋化因子介导的疾病包括:牛皮癣、特应性皮炎、骨性关节炎、类风湿性关节炎、哮喘、慢性阻塞性肺病、成人呼吸窘迫综合征、炎症性肠病、克隆氏病、溃疡性结肠炎、脑卒中、感染性休克、内毒素休克、革兰氏阴性脓毒症、中毒性休克综合征、心肾再灌注损伤、肾小球肾炎、血栓形成、移植物抗宿主反应、阿尔茨海默病、同种异体移植排斥反应、疟疾、血管再狭窄、血管生成、动脉硬化症、骨质疏松、牙龈炎、病毒性疾病(如鼻病毒)或不期望的造血干细胞释放。本发明的化合物对于治疗哮喘、慢性阻塞性肺病和成人呼吸窘迫综合征特别有用。
优选地,本发明的化合物可用于治疗慢性阻塞性肺病。
本发明的疾病的主要特征在于:大量的中性粒细胞浸润、T细胞浸润或新生血管生长,并且其与IL-8、GROα、GROβ、GROγ、NAP-2或ENA-78产量的增加相关,所述产量的增加对于中性粒细胞向炎症部位中趋化或血管内皮细胞的定向生长负有责任。与其它炎性细胞因子(IL-l、TNF和IL-6)不同,IL-8、GROα、GROβ、GROγ、NAP-2或ENA-78具有独特的性质:其促进中性粒细胞的趋化、酶的释放(包括但不限于弹性蛋白酶的释放)以及超氧化物的产生和活化。A-趋化因子,但尤其是通过IL-8I型或II型受体起作用的GROα、GROβ、GROγ、NAP-2或ENA-78,可以通过促进血管内皮细胞的定向生长而促进肿瘤的新血管形成。因此,对IL-8诱导的趋化或活化的抑制将直接导致中性粒细胞浸润减少。近来的证据也涉及趋化因子在治疗HIV感染中的作用,Littleman等人,Nature381,pp.661(1996)和Koup等人,Nature381,pp.30667(1996)。
现有证据也表明了IL-8抑制剂在治疗动脉硬化症中的用途。第一份参考文献,Boisvert等人,1.Clin.Invest,1998,101:353-363显示,通过骨髓移植,干细胞上(并因此在单核细胞/巨噬细胞上)IL-8受体的缺乏导致LDL受体缺陷小鼠中动脉粥样硬化斑块的形成减少。
本发明还提供了治疗CNS损伤的方法。此类治疗在急性期提供,以及用于在那些被认为容易受伤的个体中预防损伤。如本文中定义的CNS损伤既包括开放性或穿透性颅脑创伤(如由于外科手术),也包括闭合性颅脑创伤(如由于对头部区域的损伤)。此定义还包括了缺血性脑卒中,特别是大脑区域。缺血性脑卒中可被定义为局灶性神经功能病症,其由于特定大脑区域的血液供应不足而引起,通常是血管栓塞、血栓或局部粥样硬化闭合的结果。炎性细胞因子在此领域的作用已经浮现,而本发明提供了潜在的治疗这些损伤的方法。针对诸如此类的急性损伤的治疗尚相对缺乏。
TNF-a是具有促炎作用(包括内皮细胞白细胞粘附分子表达)的细胞因子。由于白细胞会浸润到缺血性脑损伤中,因此抑制或降低TNF水平的化合物将可用于治疗缺血性脑损伤。参见Liu等人,Stroke,Vol.25.,No.7,pp.1481-88(1994),其公开内容通过引用并入本文中。
在Shohami等人,1.ofVaisc&ClinicalPhysiologyandPharmacology,Vol.3,No.2,pp.99-107(1992)中讨论了闭合性颅脑损伤及用混合的5-LOICO药剂进行治疗的模型。据发现,减少浮肿形成的治疗能改善那些经治疗的动物的功能恢复。
如本文中所用,术语“细胞因子”指代如下的任何分泌的多肽,其影响细胞功能并且是在免疫、炎症或造血应答中调节细胞间相互作用的分子。细胞因子包括但不限于单核因子和淋巴因子,而无论其由何种细胞生产。例如,单核因子一般被认为是由单个核细胞(如巨噬细胞和/或单核细胞)生产和分泌。然而,许多其它细胞也生产单核因子,如自然杀伤细胞、成纤维细胞、嗜碱性粒细胞、中性粒细胞、内皮细胞、脑星形胶质细胞、骨髓基质细胞、表皮角质形成细胞和B淋巴细胞。
本发明的化合物可包含一种或多种其它的治疗剂或与之联合使用,并且可通过任何常规途径以单独的或组合的药物组合物依序施用或同时施用。
因此,本发明在另外的方面包括了组合产品,其包含本发明的化合物连同至少一种其它治疗活性剂。
本发明的化合物和其它药物活性剂的量以及相应的施用时序将经过选择以实现所需的联合治疗效果。
本发明的化合物和另外的治疗剂可通过施用同时包含这两类化合物的一体式药物组合物而联合使用。可选地,该组合产品可以单独的药物组合物(各包含所述化合物之一)依序分别施用,其中,例如,先施用本发明的化合物,再施用另一个,反之亦然。此类依序施用可以在时间上接近(例如同时)或间隔较远。此外,化合物是否以相同剂型施用并不重要,例如一种化合物可以局部施用,而另一种化合物可以口服。
这些组合产品可作为组合产品试剂盒提供。如本文中所用的所谓术语“组合产品试剂盒”或“套件(Kitofparts)”意指用于施用根据本发明的组合产品的药物组合物。当同时施用两种化合物时,组合产品试剂盒可在单个的药物组合物(如片剂)中或在单独的药物组合物中包含这两种化合物。当化合物不同时施用时,组合产品试剂盒将在单独的药物组合物中包含各个化合物,所述单独的药物组合物可以在单个包装中或在单独的包装中。
组合产品试剂盒还可提供说明书,如剂量和施用说明。此类剂量和施用说明可以是提供给医生的那种,例如通过药品产品标签,或其可以是由医生提供的那种,如作为给患者的说明。
当依序分别施用组合产品(其中先施用一种再施用另一种或反之亦然)时,此类依序施用可以在时间上接近或间隔较远。例如,包括了在施用第一种药剂后数分钟至数十分钟施用另一种药剂,以及在施用第一种药剂后数小时至数天施用另一种药剂,其中时间间隔不限。例如,一种药剂可以每天施用一次,而另一种药剂可以每天施用2或3次,或一种药剂可以每周施用一次,而另一种药剂可以每天施用一次,以此类推。
本领域技术人员将会清楚,在适当的情况下,其它治疗成分可以盐的形式(例如作为碱金属盐或铵盐)或作为酸式盐或前药或作为酯(例如低级烷基酯)或作为溶剂化物(例如水合物)使用,以优化治疗成分的活性和/或稳定性和/或物理特性(如溶解度)。还将清楚,在适当情况下,治疗成分可以光学纯的形式使用。
当掺混在同一组合物中时,应当理解,这两种化合物必须是稳定的并彼此相容,而且与该组合物的其它组分相容,并且可经过配制以用于施用。当单独配制时,它们可在任何便利的组合物中,以本领域中已知的用于此类化合物的方式方便地提供。
当本发明的化合物与第二种治疗活性剂被联合用于相同的疾病、状况或病症时,各化合物的剂量可以不同于当该化合物单独使用时的剂量。本领域技术人员将容易认识到合理的剂量。
本发明的化合物可与一种或多种其它药剂联合使用,所述其它药剂可用于预防或治疗变应性疾病、炎性疾病、自身免疫疾病,例如;抗原免疫疗法:抗组胺药、皮质类固醇(例如丙酸氟替卡松、糠酸氟替卡松、二丙酸倍氯米松、布地奈德、环索奈德、糠酸莫米松、曲安西龙、氟尼缩松)、NSAID、白三烯调节剂(例如孟鲁斯特、扎鲁司特、普鲁司特)、iNOS抑制剂、类胰蛋白酶抑制剂、IKK2抑制剂、p38抑制剂、Syk抑制剂、弹性蛋白酶抑制剂、β-2整联蛋白拮抗剂、腺苷a2a激动剂、趋化因子拮抗剂如CCR3拮抗剂或CCR4拮抗剂、介质释放抑制剂如色甘酸钠、5-脂氧合酶抑制剂(zyflo)、DP1拮抗剂、DP2拮抗剂、pI3Kδ抑制剂、ITK抑制剂、LP(溶血磷脂酸)抑制剂或FLAP(5-脂氧合酶激活蛋白)抑制剂(例如3-(3-(叔-丁硫基)-1-(4-(6-乙氧基吡啶-3-基)苄基)-5-((5-甲基吡啶-2-基)甲氧基)-1H-吲哚-2-基)-2,2-二甲基丙酸钠)、支气管扩张剂(例如β-2激动剂、肾上腺素激动剂、抗胆碱能药剂、茶碱)、甲氨蝶呤及类似药剂;单克隆抗体疗法如抗IgE、抗TNF、抗IL-5、抗IL-6、抗IL-12、抗IL-1及类似药剂;受体疗法例如依那西普及类似药剂;抗体非特异性免疫疗法(例如干扰素或其它细胞因子/趋化因子、细胞因子/趋化因子受体调节剂、细胞因子激动剂或拮抗剂、TLR激动剂及类似药剂)。
本发明的化合物可通过有机合成领域已知的方法制备,如下述具体实施例中所示。在所有这些方法中,良好理解的是,当必要时,根据化学基本原理可采用保护基团用于敏感或反应性基团。根据有机合成的标准方法来操控保护基团(T.W.Green和P.G.M.Wuts(1999)ProtectiveGroupsinOrganicSynthesis,第3版,JohnWiley&Sons)。使用对于本领域技术人员显而易见的方法在化合物合成的方便阶段移除这些基团。对于方法和反应条件及其执行顺序的选择应当与本发明的化合物的制备相符合。
实验
合成N-(4-氯-2-羟基-3((3S)-3-哌啶基磺酰基)苯基)-N’-(3-氟-2-甲基苯基)脲的氢溴酸盐
将N-(4-氯-2-羟基-3((3S)-3-哌啶基磺酰基)苯基)-N’-(3-氟-2-甲基苯基)脲(其可如WO2007/124424中所述制备)在50±3℃下于IPA中混悬至少30分钟以上,然后加入48wt%HBr(水中)并用水清洗冲入。将反应混合物在50±3℃下放置至少180分钟,然后加热至75±3℃。将所得溶液澄清并置于干净容器中,接着在75±3℃加入10wt%水(IPA中)。将所得溶液冷却至40±3℃,然后加入氢溴酸盐作为晶种,混悬于已经超声处理至少2分钟的10wt%水(IPA中)中。然后将所得混悬液在40±3℃下放置至少48小时,然后以0.2℃/分钟冷却至0±3℃。然后将所得混悬液在0±3℃下放置至少24小时,然后经过滤收集固体并用10wt%水(IPA中)洗涤。晶种是通过向游离碱化合物的IPA混悬液中加入cHBr而制备的,其随后被用于接种后续的和更大的批次。
将产物在50±5℃下真空干燥。该HBr盐是半水合物。
溶解度
在更高pH下和模拟肠液中,该HBr盐的溶解度高于游离碱(参见下表)。在模拟肠液中的溶解度确实随时间降低,但仍然远高于相当的游离碱溶解度。
溶出度
在pH1.6的模拟胃液和pH4的柠檬酸缓冲液中,比较胶囊中的HBr盐(50mg,以游离形式)和游离碱的溶出曲线。HBr盐更好。甲磺酸出现了胶凝,而HBr被认为优于甲磺酸盐和游离碱。参见图1和2。
Claims (16)
1.化合物,其为N-(4-氯-2-羟基-3((3S)-3-哌啶基磺酰基)苯基)-N’-(3-氟-2-甲基苯基)脲的氢溴酸盐。
2.根据权利要求1的化合物,用于治疗。
3.根据权利要求1的化合物,用于治疗CXCR2拮抗剂所指示的疾病或状况。
4.根据权利要求3所用的化合物,其中所述疾病或状况为COPD。
5.药物组合物,其包含根据权利要求1的化合物以及一种或多种药学上可接受的载体、稀释剂和赋形剂。
6.治疗个体中CXCR2拮抗剂所指示的疾病或状况的方法,其包括施用治疗有效量的根据权利要求1的化合物。
7.根据权利要求6的方法,其中所述疾病或状况为COPD。
8.根据权利要求1的化合物在制备药物上的用途,所述药物用于治疗CXCR2拮抗剂所指示的疾病或状况。
9.组合产品,其包含根据权利要求1的化合物和至少一种另外的治疗剂。
10.根据权利要求6的组合产品,用于治疗。
11.根据权利要求6的组合产品,用于治疗CXCR2拮抗剂所指示的疾病或状况。
12.根据权利要求11所用的组合产品,其中所述疾病或状况为COPD。
13.治疗CXCR2拮抗剂所指示的疾病或状况的方法,其包括向有此需要的人施用治疗有效量的根据权利要求6的组合产品。
14.根据权利要求13的方法,其中所述疾病或状况为COPD。
15.根据权利要求1的组合产品在制备药物上的用途,所述药物用于治疗CXCR2拮抗剂所指示的疾病或状况。
16.药物组合物,其包含根据权利要求6的组合产品以及一种或多种药学上可接受的载体、稀释剂和赋形剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1320021.7A GB201320021D0 (en) | 2013-11-13 | 2013-11-13 | Novel Compounds |
GB1320021.7 | 2013-11-13 | ||
PCT/EP2014/074222 WO2015071235A1 (en) | 2013-11-13 | 2014-11-11 | Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105683162A true CN105683162A (zh) | 2016-06-15 |
Family
ID=49818555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480061455.2A Pending CN105683162A (zh) | 2013-11-13 | 2014-11-11 | N-(4-氯-2-羟基-3((3s)-3-哌啶基磺酰基)苯基)-n’-(3-氟-2-甲基苯基)脲的氢溴酸盐 |
Country Status (23)
Country | Link |
---|---|
US (3) | US9809540B2 (zh) |
EP (1) | EP3068763B1 (zh) |
JP (1) | JP6401265B2 (zh) |
KR (1) | KR20160083950A (zh) |
CN (1) | CN105683162A (zh) |
AU (1) | AU2014350334B2 (zh) |
BR (1) | BR112016010409A8 (zh) |
CA (1) | CA2929907A1 (zh) |
CY (1) | CY1121581T1 (zh) |
DK (1) | DK3068763T3 (zh) |
ES (1) | ES2714721T3 (zh) |
GB (1) | GB201320021D0 (zh) |
HR (1) | HRP20190449T1 (zh) |
HU (1) | HUE041873T2 (zh) |
LT (1) | LT3068763T (zh) |
ME (1) | ME03328B (zh) |
PL (1) | PL3068763T3 (zh) |
PT (1) | PT3068763T (zh) |
RS (1) | RS58382B1 (zh) |
RU (1) | RU2685408C1 (zh) |
SI (1) | SI3068763T1 (zh) |
TR (1) | TR201902981T4 (zh) |
WO (1) | WO2015071235A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107072976A (zh) * | 2014-05-12 | 2017-08-18 | 葛兰素史克知识产权第二有限公司 | 用于治疗传染性疾病的包含Danirixin的药物组合物 |
EP3383364A1 (en) * | 2015-11-30 | 2018-10-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Formulations for intravenous injection of danirixin |
WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472477A (zh) * | 2006-04-21 | 2009-07-01 | 史密丝克莱恩比彻姆公司 | Il-8受体拮抗剂 |
-
2013
- 2013-11-13 GB GBGB1320021.7A patent/GB201320021D0/en not_active Ceased
-
2014
- 2014-11-11 LT LTEP14799988.2T patent/LT3068763T/lt unknown
- 2014-11-11 SI SI201431125T patent/SI3068763T1/sl unknown
- 2014-11-11 CA CA2929907A patent/CA2929907A1/en not_active Abandoned
- 2014-11-11 DK DK14799988.2T patent/DK3068763T3/en active
- 2014-11-11 HU HUE14799988A patent/HUE041873T2/hu unknown
- 2014-11-11 PL PL14799988T patent/PL3068763T3/pl unknown
- 2014-11-11 KR KR1020167015530A patent/KR20160083950A/ko not_active Application Discontinuation
- 2014-11-11 RU RU2016116955A patent/RU2685408C1/ru not_active IP Right Cessation
- 2014-11-11 RS RS20190230A patent/RS58382B1/sr unknown
- 2014-11-11 JP JP2016529894A patent/JP6401265B2/ja not_active Expired - Fee Related
- 2014-11-11 CN CN201480061455.2A patent/CN105683162A/zh active Pending
- 2014-11-11 EP EP14799988.2A patent/EP3068763B1/en active Active
- 2014-11-11 AU AU2014350334A patent/AU2014350334B2/en not_active Ceased
- 2014-11-11 TR TR2019/02981T patent/TR201902981T4/tr unknown
- 2014-11-11 BR BR112016010409A patent/BR112016010409A8/pt not_active IP Right Cessation
- 2014-11-11 ME MEP-2019-47A patent/ME03328B/me unknown
- 2014-11-11 PT PT14799988T patent/PT3068763T/pt unknown
- 2014-11-11 US US15/034,583 patent/US9809540B2/en active Active
- 2014-11-11 ES ES14799988T patent/ES2714721T3/es active Active
- 2014-11-11 WO PCT/EP2014/074222 patent/WO2015071235A1/en active Application Filing
-
2017
- 2017-10-05 US US15/725,429 patent/US20180079722A1/en not_active Abandoned
-
2018
- 2018-12-13 US US16/218,602 patent/US10604485B2/en not_active Expired - Fee Related
-
2019
- 2019-02-26 CY CY20191100237T patent/CY1121581T1/el unknown
- 2019-03-06 HR HRP20190449TT patent/HRP20190449T1/hr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472477A (zh) * | 2006-04-21 | 2009-07-01 | 史密丝克莱恩比彻姆公司 | Il-8受体拮抗剂 |
Non-Patent Citations (2)
Title |
---|
JACKIE C.BLOOMER,ET AL.: "Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling", 《BR J CLIN PHARMACOL》 * |
STEPHEN M. BERGE,ET AL.: "Pharmaceutical Salts", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
Also Published As
Publication number | Publication date |
---|---|
HUE041873T2 (hu) | 2019-05-28 |
PL3068763T3 (pl) | 2019-05-31 |
KR20160083950A (ko) | 2016-07-12 |
JP6401265B2 (ja) | 2018-10-10 |
US20180079722A1 (en) | 2018-03-22 |
PT3068763T (pt) | 2019-03-20 |
HRP20190449T1 (hr) | 2019-04-19 |
US10604485B2 (en) | 2020-03-31 |
DK3068763T3 (en) | 2019-03-18 |
GB201320021D0 (en) | 2013-12-25 |
TR201902981T4 (tr) | 2019-03-21 |
SI3068763T1 (sl) | 2019-04-30 |
AU2014350334B2 (en) | 2017-08-10 |
AU2014350334A1 (en) | 2016-06-02 |
BR112016010409A8 (pt) | 2020-04-22 |
LT3068763T (lt) | 2019-03-12 |
JP2016537344A (ja) | 2016-12-01 |
CA2929907A1 (en) | 2015-05-21 |
CY1121581T1 (el) | 2020-05-29 |
US9809540B2 (en) | 2017-11-07 |
EP3068763A1 (en) | 2016-09-21 |
RU2685408C1 (ru) | 2019-04-18 |
RU2016116955A (ru) | 2017-12-19 |
EP3068763B1 (en) | 2018-12-19 |
WO2015071235A1 (en) | 2015-05-21 |
US20160264525A1 (en) | 2016-09-15 |
ES2714721T3 (es) | 2019-05-29 |
RS58382B1 (sr) | 2019-04-30 |
US20190112269A1 (en) | 2019-04-18 |
ME03328B (me) | 2019-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2758686C2 (ru) | Антагонисты tlr7/8 и их применение | |
CN106715415B (zh) | 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮 | |
CN101065360B (zh) | Bay43-9006甲苯磺酸盐的热力学稳定形式 | |
CN100579527C (zh) | 用于治疗和控制脊髓发育不良综合征的含免疫调节化合物的组合物和使用方法 | |
CN103140479B (zh) | 制造嘧啶衍生物的方法 | |
CN107427476A (zh) | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 | |
US20070155679A1 (en) | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | |
CA3183081A1 (en) | Combination therapy for treatment of cancer | |
JP6619420B2 (ja) | Metap−2阻害剤としてのピロリジノン誘導体 | |
CN102413831A (zh) | 取代的咪唑并喹喔啉 | |
MXPA03004699A (es) | Sintesis de 3-amino-talidomida y sus enantiomeros. | |
CN110418796A (zh) | 托法替尼(tofacitinib)的葡萄糖苷酸前药 | |
US10604485B2 (en) | Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea | |
US20230000835A1 (en) | Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms | |
TW490465B (en) | Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof | |
JP2000500454A (ja) | 血液調節化合物 | |
CN1972686A (zh) | 选择性细胞因子抑制药在髓发育不良综合征中的用途 | |
CN110381949A (zh) | 杂环化合物及其用途 | |
CN108658843B (zh) | 乙酰苄胺哌啶酰胺类衍生物及其作为脑神经保护剂的应用 | |
AU2017342262A1 (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
CN1308629A (zh) | 粒度减小形式的1-(6-氯萘-2-基磺酰基)-4-[4-(4-吡啶基)苯甲酰基]哌嗪 | |
WO2003089426A1 (fr) | Medicament prophylactique ou therapeutique contre le syndrome de coagulation intravasculaire disseminee | |
CN102076672A (zh) | 新型五元环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |